Stem cells improve post-infarct heart function
Chicago, IL -
The use of bone marrow stem cells post infarct has been reported to induce improvements in various cardiac parameters post-infarct. In fact, even administration of stem cells in patients after chronic cardiac deterioration has been reported to have beneficial effects, although these are much more rare.
Singh et al (Stem cells improve left ventricular function in acute myocardial infarction. Clin Cardiol. 2009 Apr;32(4):176-80) have reported a meta-analysis of 6 randomized controlled trials whose primary endpoint was change in global left ventricular ejection fraction (LVEF) baseline to follow-up (ranging between 3 to 6 months).
Of 516 patients (BMC group, 256; control group, 260) in the 7 trials there were no significant differences in patient characteristics between the BMC treatment and control groups at baseline. Post-treatment, compared to the control group, patients in the BMC treatment group had significantly greater increase in LVEF from baseline to follow-up (mean difference: 6.108%; SE: 1.753%; 95% confidence interval [CI]: 2.672%- 9.543%; P<.001).
These data suggest that the simple procedure of post-infarct bone marrow infusion may be useful in stopping progression to heart failure after heart attacks.
Social & Bookmarking:
1 Comment | Add Comment
Add Comment
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.
W said...
This website/organization is so important because among other things it shines a light
on the very little understood area of the stem cell patents minefield. With so many patents 1400plus and more coming each day , from around the world, it is not hard to imagine , from a IP prospective, that a huge patent litigation storm is on the horizon .
With billions of dollars at stake, the most powerful companies will be litigating / getting TRO's and injunctions on weaker and not properly defended smaller companies, that may be forced to sell their IP, for pennies on the dollar.
Not only does this hurt this wonderful emerging industry, but it will substantially delay the introduction of these life saving therapies to the most critically ill patients that need these so desparately, right now.